Nitric Oxide–Containing Nanoparticles as an Antimicrobial Agent and Enhancer of Wound Healing  by Weller, Richard B.
commentary
 www.jidonline.org 2335
E, Weber M (2005) Successful treatment of a 
severe case of idiopathic pulmonary fibrosis with 
rapamycin. Med Klin 100:161–4
Ekici Y, Emiroglu R, Ozdemir H, Aldemir D, 
Karakayli H, Haberal M (2007) Effects of 
rapamycin on wound healing: an experimental 
study. Transplant Proc 39:1201–3
Gozuacik D, Kimchi A (2007) Autophagy and cell 
death. Curr Top Dev Biol 78:217–45
Kalla S, Dutz JP (2007) New concepts in antimalarial 
use and mode of action. Dermatol Ther 
20:160–74
Kim WU, Yoo SA, Min SY, Park SH, Koh HS, Song SW 
et al. (2006) Hydroxychloroquine potentiates Fas-
mediated apoptosis of rheumatoid synoviocytes. 
Clin Exp Immunol 144:503–11
Liang XH, Jackson S, Seaman M, Brown K, Kempkes 
B, Hibshoosh H et al. (1999) Induction of 
autophagy and inhibition of tumorigenesis by 
beclin-1. Nature 402:672–6
Meng XW, Feller JM, Ziegler JB, Pittmann SM, Ireland 
CM (1997) Induction of apoptosis in peripheral 
blood lymphocytes following treatment in vitro 
with hydroxychloroquine. Arthritis Rheum 
40:927–35
Potvin F, Petitclerc E, Marceau F, Poubelle PE 
(1997) Mechanism of action of antimalarials in 
inflammation: induction of apoptosis in human 
endothelial cells. J Immunol 158:1872–9
Ramser B, Kokot A, Metze D, Weiß N, Luger TA, 
Böhm M (2009) Hydroxychloroquine modulates 
metabolic activity and proliferation and induces 
autophagic cell death of human dermal 
fibroblasts. J Invest Dermatol 129:2419–26
Wang C-W, Klionsky DJ (2003) The molecular 
mechanism of autophagy. Mol Med 9:65–76
See related article on pg 2463
nitric Oxide–containing nanoparticles 
as an Antimicrobial Agent and 
enhancer of Wound Healing
Richard B. Weller1
nitric oxide (nO) is known to be involved in wound healing and to have 
antimicrobial actions. Developing a means of delivering a diatomic, gaseous 
free radical has been a technical challenge. Using a combination of techniques, 
Martinez and colleagues have developed an ingenious method of storing nO, and 
they demonstrate its efficacy in treating infected wounds.
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Nitric oxide (NO) biology has been a 
subject of intense study over the past 
15 years, but clinical applications have 
lagged behind our growing under-
standing of its varied biological roles. 
First described as endothelium-derived 
relaxant factor, the elucidation of the 
mechanism by which this soluble, 
short-half-life mediator is released from 
endothelial cells to dilate adjacent vas-
cular smooth muscles via the cyclic 
guanosine monophosphate (cGMP) 
and its subsequent identification as 
NO earned a Nobel Prize in Medicine 
for Drs. Furchgott, Ignarro, and Murad 
in 1998.
NO has a far wider range of actions 
than simply vasodilatation, and the 
discovery that carbon monoxide is bio-
logically active indicates it may be the 
prototype of a new class of small free-rad-
ical messengers. These diatomic free radi-
cals interact with enzymes, particularly 
those containing transition metals, to acti-
vate or inhibit them. NO is produced by 
a family of three NO synthases (NOSs), 
with arginine as the substrate. Endothelial 
and neuronal NOSs are constitutively 
expressed, whereas inducible NOSs 
(iNOSs) release much higher concen-
trations of NO in response to a number 
of cell-specific stimuli. Nonenzymatic 
production of NO by the reduction of 
nitrite and nitrosothiols, in particular, also 
occurs. Both enzymatic and nonenzy-
matic mechanisms of production occur 
in or on the skin. NO plays a part in 
keratinocyte growth and differentiation, 
apoptosis regulation, platelet aggrega-
tion, neurotransmission, control of oxy-
gen delivery, and vaso dilatation. Aberrant 
regulation of NO is a feature of septic 
shock and pulmonary hypertension, as 
well as inflammatory conditions such as 
psoriasis and rheumatoid arthritis.
no as an anti-infective agent
NO is important in the innate immune 
system (Fang, 2004). Stimulation of 
microbial pattern recognition receptors 
in phagocytic cells leads to iNOS trans-
cription and high-output NO production. 
NO can interfere directly with DNA rep-
lication and cell respiration through the 
inactivation of zinc metalloproteins, but 
it more commonly interacts with simul-
taneously produced reactive oxygen 
species to generate an array of reactive 
nitrogen intermediates. This allows finely 
regulated production of a spatially and 
temporally restricted array of antimicro-
bial effector molecules acting on differ-
ent targets within the microbial cell. NO 
donors have demonstrated promise as 
antimicrobial agents, but in most of these 
systems NO is reported to act in combi-
nation with other agents (Weller et al., 
2001; Lopez-Jaramillo et al., 1998). Its 
efficacy as an independent antimicrobial 
has been less well defined.
no and wound healing
NO is produced by healing wounds, and 
its known roles in angiogenesis, colla-
gen deposition, and keratinocyte pro-
liferation all indicate that its production 
is an important part of the wound heal-
ing cascade. Experiments demonstrating 
that pharmacological or genetic (NOS 
knockout) reduction of NO impairs the 
speed and effectiveness of wound heal-
ing and that this process can be reversed 
by restoring NO production with 
increased NOS substrate (arginine) or by 
transfecting with the missing NOS gene 
(Yamasaki et al., 1998) confirm this sug-
gestion. Furthermore, a number of nitric 
oxide donors have exhibited benefit in 
experimental wound models (Weller and 
Finnen, 2006; Luo and Chen, 2005).
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no donors
Devising a means of storing a small, 
gaseous free radical has been a consid-
erable technical challenge, requiring a 
different approach from the mechanism 
of currently available pharmaceuticals, 
which are complex molecules with 
action and specificity that rely on their 
three-dimensional shape and receptor–
agonist interactions. NO has a short 
half-life and high reactivity and, being 
lipophilic, readily crosses cell walls 
and diffuses rapidly down a concentra-
tion gradient from its site of production. 
Specificity of action relies on the ability 
of NO to be either produced or released 
at the required site and at a rate high 
enough to generate a concentration gra-
dient. The ideal donor drug would store 
NO stably at room temperature for an 
extended time and release it consistently 
when required at the pharmacologically 
specified dose and with a long enough 
duration to exert its biological action. 
The agent should be nontoxic and non-
inflammatory. Several NO donors have 
been developed to meet these criteria, 
and the accessibility of the skin makes it 
an ideal organ in which to develop NO 
donor-based treatments.
At the simplest level, inhaled gas-
eous NO has been used to treat pul-
monary hypertension and respiratory 
distress syndrome, but a gaseous form 
would be impractical for skin dis-
ease. NO-containing compounds such 
as nitrosothiols, NO-binding organic 
molecules, and nitrosated thiosugars, 
which will break down in contact with 
the skin, have been tested in humans. 
Nitrosothiols (–SNOs) are formed by the 
reaction of NO with thiol groups, and 
they are biologically active. In addition, 
the nitrosothiol bond is relatively unsta-
ble and liberates NO in the presence of 
ultraviolet radiation, copper, or mercu-
ry. Direct transnitrosation reactions can 
also occur with adjacent thiol groups, 
which are plentiful in the cysteine-rich 
stratum corneum and may prolong the 
actions of nitrosothiol. Nitrosated thio-
sugars (Khan et al., 2003) undergo ther-
mal decomposition.
A second approach to delivering NO 
is to use a more stable precursor, which 
can be chemically activated at the time 
of application. Two-part creams in which 
nitrite is mixed with thiols can be used to 
form nitrosothiols at the time of applica-
tion. Alternatively, nitrite can be mixed 
with an acid such as ascorbate, leading 
to the reduction of nitrite and the release 
of NO:
NO2
– + H+ ↔ HNO2
2HNO2 ↔ N2O3 + H2O
N2O3 + NO• + NO2
The chemistry is more complex than 
this simple equation illustrates, how-
ever, and a number of reactive nitro-
gen intermediates are also released, 
depending on the acid used. Acidified 
nitrite has been used successfully to 
treat cutaneous fungal, leishmanial, and 
mycobacterial infections (Fang, 2004), 
and it hastens wound healing in normal 
and diabetic mice (Weller and Finnen, 
2006). The precise biological effects of 
acidified nitrite creams depend on the 
pKa and type of acid used as a reducing 
agent, but they may cause inflammation. 
Placing a semipermeable membrane 
between the skin surface and mixed 
creams mitigates the inflammatory 
effects of acidified nitrite, while allow-
ing NO delivery (Hardwick et al., 2001). 
The undoubted antimicrobial efficacy of 
acidified nitrite-based treatments may 
rely on the range of nitrogen oxides pro-
duced, in addition to NO.
Finally, local NO storage and deliv-
ery are possible in nanoporous materi-
als. Zeolites, which can contain large 
quantities of NO reversibly constrained 
within their lattice structure, are the pro-
totypic microporous material. Structural 
alterations in pore size and chemically 
bound metal ions within the zeolite 
allow modulation of the rate and extent 
of NO release (Mowbray et al., 2008). 
Exposure to moisture, such as that found 
on the skin surface, triggers NO release 
as water enters the lattice structure and 
exchanges for NO.
Martinez et al. (2009, this issue) 
describe a novel NO-releasing cream that 
uses a combination of these methods. 
The same group previously developed 
a hydrogel/glass composite that is syn-
thesized using tetramethylortho silicate, 
polyethylene glycol, and chitosan to form 
the NO-bearing composite, and nitrite 
and glucose to form NO (Friedman et al., 
2008). During the preparation process, 
the mixture is heated to 70 ºC, under 
which conditions glucose reduces nitrite 
to release NO, which remains trapped 
within the composite structure. The 
resulting composite is milled and desic-
cated to form nanoparticles from which 
NO is released upon exposure to water. 
The rate of release can be controlled by 
modifying the size of polyethylene glycol 
molecules, and the amount of NO load-
ed into the nanoparticles can be deter-
mined by the initial nitrite concentration.
A number of previous studies have 
demonstrated reductions in wound heal-
ing times with NO donor treatment (Luo 
and Chen, 2005; Weller and Finnen, 
2006), but this is the first study in which 
such a donor exhibits simultaneous 
wound healing and antimicrobial bene-
fits. Methicillin-resistant Staphylococcus 
aureus and the increased incidence 
of chronic leg ulceration in an aging 
population are significant public health 
problems. The advent of a technology 
that may benefit both—individually or 
jointly—seems promising. The NO 
released by the nanoparticles described 
by Martinez et al. may be solely respon-
sible for their antimicrobial properties, 
in which case other topical NO donors 
would be expected to have similar 
effects. Alternatively, there may be syn-
ergy between NO and the chitosan in 
the nanoparticle composite.
A considerable body of evidence sug-
gests that topical NO donors improve 
wound healing, and a number of poten-
tial agents have demonstrated efficacy in 
animal models. Clinical trials are needed 
to determine which of these agents is 
most likely to be effective in humans. The 
timing of application of a NO donor after 
wounding will probably be an important 
variable. Previous murine experiments 
have shown that NO donors are effective 
in improving wound healing only when 
application starts 2 to 4 days after injury 
(Weller and Finnen, 2006). This indicates 




that additional NO is beneficial only at 
certain phases in the wound healing 
cascade, and different wounds may 
require different NO donors. Infected 
wounds would be an obvious target for 
nanoparticle NO (Martinez et al., 2009), 
whereas other NO donors have exhibit-
ed efficacy at healing wounds in diabetic 
mice. Somewhat counterintuitively, the 
relatively large number of NO donors 
shown to improve wound healing seems 
to have slowed the clinical development 
of this family of drugs. The ubiquity and 
simplicity of NO have produced a com-
plex intellectual property environment 
in which the pharmaceutical industry, 
the government, and charitable donors 
are unwilling to fund clinical trials lest 
they lose the commercial benefits result-
ing from a successful outcome to a pat-
ent holder with a competing claim. One 
hopes that such concerns will not hinder 
the clinical development of this promis-
ing line of therapies.
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spitting Image:  
Tick saliva Assists the causative Agent 
of Lyme Disease in evading  
Host skin’s Innate Immune Response
Joppe W.R. Hovius1
Lyme disease is caused by the spirochete Borrelia burgdorferi and is transmit-
ted through ticks. Inhibition of host skin’s innate immune response might be 
instrumental to both tick feeding and B. burgdorferi transmission. The article 
by Marchal et al. describes how tick saliva suppresses B. burgdorferi–induced 
antimicrobial peptide production. This inhibition directly facilitates survival of 
the spirochete and might lead to diminished chemotaxis of leukocytes toward 
the site of the tick bite.
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Lyme disease, or Lyme borreliosis, was 
first recognized as a distinct clinical enti-
ty in 1975 in Old Lyme, Connecticut, 
in children at the Yale–New Haven 
Hospital who were initially thought 
to have juvenile rheumatoid arthritis 
(Steere et al., 1977). Previously, how-
ever, certain clinical signs of the disease 
had been described in Europe (Afzelius, 
1921). Ixodes scapularis, Ixodes ricinus, 
and Ixodes persulcatus are the most 
important vectors for Lyme borreliosis 
in the United States, Europe, and Asia, 
respectively, and the disease is caused 
by spirochetes of the Borrelia burgdor-
feri sensu lato group (Wang et al., 1999). 
In Europe and Asia, three major Borrelia 
genospecies (B. burgdorferi sensu stric-
to, Borrelia garinii, and Borrelia afzelii) 
are the causative agents. By contrast, 
only B. burgdorferi sensu stricto strains 
are present in the United States. The 
obligate enzootic life cycle of the spi-
rochetes involves ticks, primarily Ixodes 
ticks, and a variety of vertebrate hosts, 
including small rodents, large mammals, 
and birds (Anderson and Magnarelli, 
1980). In general, uninfected tick lar-
vae acquire the bacterium by feeding on 
infected animals. Ticks remain infected 
during their consecutive molting peri-
ods, enabling both nymphal and adult 
ticks to transmit spirochetes to (larger) 
animals and humans.
To secure attachment of the tick 
and to ensure susceptibility of reser-
voir hosts for future tick infestations, 
tick saliva contains modulators of host 
immune responses. During the course 
of a blood meal, which can take up to 
seven days, ticks introduce saliva con-
taining a wide range of physiologically 
active components. Immunosuppressive 
proteins in tick saliva interfere with 
